CClinicalTrials.gg
Status unknownNCT03247166Updated Aug 11, 2017

A Study to Evaluate the Safety and Effectiveness of the TOPS™ SP System

An interventional study of TOPS™ System in Lower Back Pain, sponsored by Hillel Yaffe Medical Center. Status unknown at 1 site in Israel. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-08-11.

Sponsored by Hillel Yaffe Medical Center · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Aug 2017), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
40 Years to 85 Years
Sex
All
01

Study summary

The TOPS™ SP System is intended to provide stabilization in skeletally mature patients. The system is designed to afford motion of the spine segment without fusion. The pur0pose of this prospective clinical study is to establish the safety and effectiveness of the TOPS™ System, when used following decompression, in the treatment of lower back and sciatic pain.

02

Conditions studied

  • Lower Back Pain

Browse trials for

03

In context

Low Back Pain

2,818 studies on the registry are indexed under Low Back Pain; 482 are open to participants now.

This study's planned enrollment of 10 is below the median of 60 across 2,268 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

Hillel Yaffe Medical Center is the lead sponsor of 301 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with symptomatic monosegmental lumbar spinal stenosis or facet arthrosis
  • Patients with degenerative spondylolisthesis
  • Patients with at least 3 months failed conservative treatment
  • Narrowing of the lumbar spinal canal
  • Patients with lower back pain or sciatica

Exclusion criteria

Exclusion Criteria:

  • Discogenic back pain at TOPS System level
  • Back or non-radicular leg pain of unknown etiology at TOPS System level
  • Lytic spondylolisthesis at TOPS System level
  • More than one motion segment involved in degenerative pathology to the extent that justifies its inclusion in the surgical procedure
  • Known allergy to titanium and/or polyurethane
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Lower Back and Leg Pain Patients

    Patients suffering from lower back and leg pain resulting in degenerative spondylolisthesis and/or spinal stenosis will undergo treatment using the TOPS™ System

    Device: TOPS™ System

Interventions

  • DeviceTOPS™ System

    The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints

06

What researchers measure

Primary outcomes

  1. Pain Improvement

    Subjects having a 15% reduction in the Oswestry Low Back Pain Disability Questionnaire score as compared to their preoperative Oswestry score

    Time frame: 24 months

  2. Function Improvement

    Subjects having a 15% reduction in the Oswestry Low Back Pain Disability Questionnaire score as compared to their preoperative Oswestry score

    Time frame: 24 months

  3. Fusion Prevention

    The subjects will be considered a failure if fusion occurs as defined in the radiographic protocol

    Time frame: 24 months

Other outcomes

  1. Safety

    Subjects with no serious device complications as defined in the radiological protocol

    Time frame: 24 months

07

Study locations

1 site
  • Hillel Yaffe Medical Center
    H̱adera, 38100, Israel
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03247166
Lead sponsor
Hillel Yaffe Medical Center
Responsible party
Sponsor
First posted
Aug 11, 2017
Start date
Sep 2017 (estimated)
Primary completion
Sep 2019 (estimated)
Completion
Sep 2019 (estimated)
Last update
Aug 11, 2017

Study contacts

Ilana Alony, RN
Contact
ilanaa@hy.health.gov.il
972-4-6304487
Eyal Behrbalk, MD
principal investigator · Hillel Yaffe Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion